Although our findings are just the tip of the iceberg and many other mechanisms are yet-to-be-discovered, it is possible that the BRCA1 status can be used as one of the biomarkers to forejudge the taxane sensitivity of HNSCC with acquired CDDP resistance. The gene discussed is BRCA1; the disease is head and neck squamous cell carcinoma.